星輝娛樂(300043.SZ):擁有《三國羣英傳》《鬥破蒼穹》《仙境傳説》《冒險島》等多款IP授權
格隆匯5月6日丨星輝娛樂(300043.SZ)於2023年5月5日召開業績説明會,就“想諮詢下是不是遊戲的業務有所改善了?《戰地無疆》和《冒險島:聯盟的意志》預期如何,2023年及以後有哪些產品會推出以及儲備的情況如何?目前遊戲業務IP的變化情況如何?”,公司表示,在今年整體遊戲行業回暖的大形勢下,公司產品矩陣得到優化,公司全資子公司星輝天拓的《戰地無疆》於2022年7月審批通過獲得版號;公司全資子公司上海悠玩的《冒險島:聯盟的意志》於2023年3月審批通過獲得版號;並擁有《三國羣英傳》《鬥破蒼穹》《仙境傳説》《冒險島》等多款IP授權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.